←Psychosis Risk
Study register · detail Longitudinale Co-Twin-Control-Analyse · Psychosis Risk · 2021

Supplemental Material for Adolescent Cannabis Use and Adult Psychoticism: A Longitudinal Co-Twin Control Analysis Using Data From Two Cohorts

Journal of Abnormal Psychology
No direction reported 0 citations
Sample—
DesignLongitudinale Co-Twin-Control-Analyse
Summary

Longitudinal twin study on adolescent cannabis use and adult psychoticism; co-twin control design to control for genetic and environmental confounding. Abstract does not report numerical effect sizes; refers to a consistent association between cannabis use and increased schizophrenia risk (Marconi et al., 2016) as well as a dose-dependent increase in risk with early onset of use (van der Steur et al., 2020).

Quality profile
Sample size —
Blinding —
Effect size —
Citations / year ★★★★★
DOI 10.1037/abn0000701.supp↗
Design: Longitudinale Co-Twin-Control-Analyse
Share
Indication
Further studies on Psychosis Risk
All studies →
S Marconi et al. · 2016 · Schizophrenia Bulletin
860 citations
Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis
Clear benefit Meta-Analyse

Meta-Analyse über 10 Studien (n≈66.816) zur Dosis-Wirkungs-Beziehung zwischen Cannabis-Konsum und Psychose-Risiko; OR=3.90 (95% CI 2.84–5.34) für täglichen vs. Nicht-Konsum, OR=1.97 (1.68–2.31) für jeglichen Konsum vs. Nie-Konsum; klare Evidenz für erhöhtes Psychose-Risiko bei stärkerem Cannabis-Gebrauch.

10.1093/schbul/sbw003 View study →
S Andréasson et al. · 1987 · The Lancet
1144 citations
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.
Harm Prospektive Kohortenstudie

Landmark-Kohortenstudie (n=45.570 schwedische Wehrpflichtige, 15 Jahre Follow-up); Hochkonsumenten (>50 Gelegenheiten) RR=6,0 (95%-KI 4,0–8,9) für Schizophrenie; Dosis-Wirkungs-Gradient; Cannabis als unabhängiger Schizophrenie-Risikofaktor nach multivariater Adjustierung bestätigt.

10.1016/s0140-6736(87)92620-1 View study →
S Di Forti et al. · 2019 · The Lancet Psychiatry
844 citations
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
Harm Multizentrisches Fall-Kontroll-Studie

Multizentrische EU-GEI Fall-Kontroll-Studie (n=901 Fälle, n=1237 Kontrollen, 11 europäische Standorte): täglicher Cannabiskonsum OR=3,2 (95%-KI 2,2–4,1) für psychotische Störung; täglicher Hochpotenz-Cannabis OR=4,8 (95%-KI 2,5–6,3). Populationsattributabler Anteil (PAF) für Hochpotenz-Cannabis: 12,2% gesamt, 30,3% in London, 50,3% in Amsterdam. Inzidenzrate korrelierte positiv mit Hochpotenz-Prävalenz (r=0,7; p=0,0286) und täglichem Konsum (r=0,8; p=0,0109).

10.1016/s2215-0366(19)30048-3 View study →

The impediment to action advances action. — Marcus Aurelius